Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | ITK | Q08881 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15755731 | 0.94 | CHEK1 (0.47) | CHEK1CDK7USP30PIK3CACYP2D6 | |
| SCHEMBL29470283 | 0.91 | CHEK1 (0.47) | CHEK1CDK7USP30PIK3CAPCSK9 | |
| SCHEMBL6125647 | 0.91 | CHEK1 (0.47) | CHEK1CDK7USP30PIK3CAPCSK9 | |
| SCHEMBL29470528 | 0.89 | CHEK1 (0.51) | CHEK1CDK7USP30PCSK9LCK | |
| SCHEMBL6125937 | 0.89 | CHEK1 (0.51) | CHEK1CDK7USP30PCSK9LCK | |
| SCHEMBL8739542 | 0.89 | LCK (0.45) | USP30PIK3CACYP2D6CYP2C19PCSK9 | |
| SCHEMBL8739170 | 0.88 | PIK3CA (0.41) | CHEK1PIK3CACYP2D6CYP2C19KDR | |
| SCHEMBL20461863 | 0.88 | CHEK1 (0.47) | CHEK1CDK7USP30PIK3CAPCSK9 | |
| SCHEMBL15673565 | 0.88 | CHEK1 (0.48) | CHEK1CDK7USP30PIK3CAPCSK9 | |
| SCHEMBL6125772 | 0.88 | CHEK1 (0.46) | CHEK1CDK7CYP2D6CYP2C19KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-10-18 | — | — | US | claimed |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | claimed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | claimed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-07-09 | — | — | US | disclosed |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012068546-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-11186593-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885CDK7 780/4885USP30 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.